Aldeyra Therapeutics, Inc. (ALDX) — insider trading
Health Care · Nasdaq
Aldeyra Therapeutics, Inc. (ALDX) has 22 reported SEC Form 4 insider transactions in our data, including 3 open-market purchases among the most recent 22 (latest 2026-06-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | DEPTULA-HICKS DARLENE M | Director | Grant / award / vesting (derivative) | 9,756 | $0.00 | $0 | Form 4 |
| 2026-06-09 | DEPTULA-HICKS DARLENE M | Director | Grant / award / vesting (derivative) | 84,557 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Bronstein Ben | Director | Grant / award / vesting (derivative) | 4,977 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Bronstein Ben | Director | Grant / award / vesting (derivative) | 5,309 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Bronstein Ben | Director | Grant / award / vesting (derivative) | 70,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Walker Neal | Director | Grant / award / vesting (derivative) | 3,318 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Walker Neal | Director | Grant / award / vesting (derivative) | 70,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Clark William D | Director | Grant / award / vesting (derivative) | 2,323 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Clark William D | Director | Grant / award / vesting (derivative) | 70,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Phillips Gary M. | Director | Grant / award / vesting (derivative) | 4,977 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Phillips Gary M. | Director | Grant / award / vesting (derivative) | 6,636 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Phillips Gary M. | Director | Grant / award / vesting (derivative) | 70,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | DOUGLAS RICHARD | Director | Grant / award / vesting (derivative) | 2,323 | $0.00 | $0 | Form 4 |
| 2026-06-09 | DOUGLAS RICHARD | Director | Grant / award / vesting (derivative) | 19,909 | $0.00 | $0 | Form 4 |
| 2026-06-09 | DOUGLAS RICHARD | Director | Grant / award / vesting (derivative) | 70,000 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Miller-Rich Nancy | Director | Grant / award / vesting (derivative) | 3,318 | $0.00 | $0 | Form 4 |
| 2026-06-09 | Miller-Rich Nancy | Director | Grant / award / vesting (derivative) | 70,000 | $0.00 | $0 | Form 4 |
| 2026-06-03 | Brady Todd C | Director, Officer (President and CEO) | Open-market purchase | 250,000 | $1.67 | $418.4K | Form 4 |
| 2026-03-27 | Brady Todd C | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 632,318 | $0.00 | $0 | Form 4 |
| 2026-03-27 | Brady Todd C | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 1,880,510 | $0.00 | $0 | Form 4 |
| 2026-03-19 | DOUGLAS RICHARD | Director | Open-market purchase | 70,000 | $1.40 | $98.0K | Form 4 |
| 2026-03-18 | Alfieri Michael | Officer (Principal Financial Officer) | Open-market purchase | 5,000 | $1.42 | $7.1K | Form 4 |
Ask the chat about ALDX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Aldeyra Therapeutics, Inc. (ALDX).
Last updated 2026-06-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.